Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tharimmune, Inc. - Common Stock (NQ:THAR)

3.360 +0.330 (+10.89%)
Streaming Delayed Price Updated: 11:35 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tharimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
News headline image
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Tharimmune (THAR) Shares Are Moving ↗
Tharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split. 
Via Benzinga
News headline image
THAR Stock Earnings: Tharimmune Reported Results for Q4 2023 ↗
Tharimmune just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
Via ACCESSWIRE
News headline image
Why Tharimmune (THAR) Shares Are Getting Hammered ↗
Tharimmune shares are trading lower by 30% during Monday's session. The company late Friday announced it had entered into an "at the market" offering agreement. 
Via Benzinga
News headline image
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
News headline image
Tharimmune to Present at 2024 BIO International Convention
Via ACCESSWIRE
News headline image
Why Is Verastem (VSTM) Stock Down 62% Today? ↗
Verastem stock is down on Friday with heavy trading of VSTM shares alongside its latest pancreatic cancer clinical trial safety data. 
Via InvestorPlace
News headline image
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? ↗
Sensei Biotherapeutics stock is falling on Friday as SNSE investors are unimpressed by its latest clinical trial data. 
Via InvestorPlace
News headline image
Why Is Tharimmune (THAR) Stock Moving Today? ↗
Tharimmune stock is on the move Friday as investors prepare for a reverse split of THAR shares after markets close today. 
Via InvestorPlace
News headline image
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Via ACCESSWIRE
News headline image
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Via ACCESSWIRE
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tharimmune Announces 1-for-15 Reverse Stock Split
Via ACCESSWIRE
Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
News headline image
Tharimmune To Participate in Two Upcoming Investor Conferences in May
Via ACCESSWIRE
News headline image
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Via ACCESSWIRE
News headline image
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Via ACCESSWIRE
News headline image
Tharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease ↗
Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential for liver-related conditions. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying ↗
The Dow Jones index closed slightly higher on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Topics Stocks
News headline image
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
Via ACCESSWIRE
News headline image
Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
Shares of Hello Group Inc. (NASDAQ: MOMO) jumped in pre-market trading after reporting results for the third quarter. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.